作者
David Qualls,Nicholas Lambert,Paolo F. Caimi,Mwanasha Merrill,Priyanka Pullarkat,Richard C. Godby,David A. Bond,Graham T. Wehmeyer,Jason T. Romancik,Behzad Amoozgar,Lori A. Leslie,Loretta J. Nastoupil,Jennifer L. Crombie,Jeremy S. Abramson,Arushi Khurana,Grzegorz S. Nowakowski,Kami J. Maddocks,Sarah C. Rutherford,Brad S. Kahl,Michelle Okwali,Michael J. Buege,Venkatraman Seshan,Connie Lee Batlevi,Gilles Salles
摘要
Abstract In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.